Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amplification of the <i>TOP2A</i> gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples

22 Jan 2004

Abstract excerpt

Recent clinical trials have suggested that patients whose breast tumors overexpress HER2 may derive particular benefit from anthracycline-containing chemotherapy compared to that without anthracycline. It has been proposed that the HER2 gene amplification reported in these tumors might mask an underlying TOP2A gene amplification that occurs frequently and concurrently with HER2 amplification. Topoisomerase II...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to HER2/EGFR in Cancer Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14978790
DOI: 10.1002/gcc.20008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amplification of the <i>TOP2A</i> gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samplesPMID 14978790Read ↗

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and PredictionSemantic proximity Read ↗

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Semantic proximity Read ↗

HER-2/neu and Topoisomerase IIα Gene Amplification and Protein Expression in Invasive Breast CarcinomasSemantic proximity Read ↗

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancerSemantic proximity Read ↗

c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective studySemantic proximity Read ↗

Aberrations of <i>ERBB2</i> and <i>TOP2A</i> genes in breast cancerSemantic proximity Read ↗

The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridization studySemantic proximity Read ↗

Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase II&#945; (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in CancerSemantic proximity Read ↗

The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsSemantic proximity Read ↗

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyondSemantic proximity Read ↗

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Semantic proximity Read ↗

Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.